What does the expense ratio mean when comparing ETFs?

The expense ratio is the annual fee charged by a fund to manage its assets. When comparing IBB (iShares Biotechnology ETF) and XLV (Health Care Select Sector SPDR), XLV has a lower expense ratio of 0.08%, compared to IBB's 0.44%. Over time, this difference can impact net returns, as lower fees allow more of the investment to remain invested and compound.

How do ETFs distribute dividends, and what do yields signify?

ETFs distribute dividends collected from their underlying holdings to shareholders. The dividend yield represents the annual dividends paid relative to the ETF's share price. IBB yields 0.16%, reflecting biotechnology companies typically reinvesting earnings into research and growth. Conversely, XLV yields 1.51%, indicating that the broader health care sector includes companies more inclined to pay regular dividends.

What is meant by sector exposure in ETFs?

Sector exposure describes the market segment where a fund's assets are concentrated. IBB focuses on biotechnology, which involves high-growth potential but often comes with higher volatility. XLV provides access to the broader health care sector, including pharmaceuticals and healthcare providers. Understanding these differences helps investors gauge risk and align investments with personal preferences regarding sector performance and stability.

How do the holdings of IBB and XLV differ?

IBB targets the biotechnology segment with holdings like Gilead Sciences and Vertex Pharmaceuticals, while XLV covers the entire health care sector, featuring companies such as Eli Lilly and Johnson & Johnson. Both funds share some overlap, like Gilead Sciences and Amgen, yet their broader portfolios reflect distinct industry focuses, with IBB leaning towards innovation-driven biotech and XLV towards diversified healthcare services and products.

Why do ETFs have overlapping holdings?

ETFs may have overlapping holdings if they track similar or related sectors. For example, IBB and XLV both include Gilead Sciences and Amgen in their top 10 holdings, reflecting shared presence in health care and biotechnology industries. However, the rest of their portfolios diverge significantly due to differing investment focuses—IBB being biotechnology-specific, while XLV is broader health care sector-based.

Which ETF might suit an investor seeking regular income?

An investor seeking regular income could find XLV more suitable due to its 1.51% dividend yield. This higher yield reflects the fund's composition, which includes established health care companies known for paying regular dividends. In contrast, IBB's minimal 0.16% yield aligns with biotechnology firms often reinvesting profits to fuel growth and development, offering limited regular income to investors.

How do concentration risks affect these ETFs?

Concentration risk is present when a fund heavily weights its portfolio in one or a few holdings. For XLV, Eli Lilly represents 15.17% of the fund, creating a notable concentration risk. In IBB, although no single stock exceeds 10%, the presence of volatile names like Moderna and Vertex increases portfolio risk. Investors should consider these concentration levels when evaluating potential impacts on fund performance.

How has the market performance influenced these ETFs' sizes?

XLV commands a larger net assets of $43.5 billion compared to IBB's $10.4 billion, reflecting potentially broader market demand and liquidity in health care sector investing. The size discrepancy also highlights IBB's specialised focus on biotechnology, which may attract less widespread investor interest despite its long operational history since February 2001.

What do the top holdings tell us about market trends?

The top holdings of IBB and XLV provide insights into current market trends within health care and biotechnology sectors. While IBB's portfolio includes growth-oriented firms like Vertex and Moderna, XLV's holdings such as Eli Lilly and Johnson & Johnson indicate a preference for established, stable companies. This divergence reflects varying investor appetites for growth versus stability across different market phases.

How does liquidity impact the choice between IBB and XLV?

Liquidity impacts trading efficiency and cost. XLV, with $43.5 billion in net assets, likely offers higher liquidity compared to IBB's $10.4 billion. Higher liquidity means potentially tighter bid-ask spreads and ease of trading for XLV, whereas IBB's lower liquidity might increase transaction costs and make large trades less favourable.

What should beginners know about reading ETF comparisons?

Beginners should focus on key metrics like expense ratios, dividend yields, and holdings to understand ETF comparisons. Look at IBB's 0.44% expense ratio versus XLV's 0.08%, and note their different yields (0.16% vs. 1.51%). Also, consider sector focus and top holdings. This educational disclaimer is included to remind that this content is for informational purposes only and does not constitute financial advice.

IBB vs XLV

Two funds, one decision: we compare cost, performance and what each ETF actually holds in October 2026.

Compare IBB (iShares Biotechnology ETF) and XLV (Health Care Select Sector SPDR). This page examines fees, holdings and dividends, and how each fund tracks its market. IBB has a 0.44% expense ratio and 0.16% dividend yield, while XLV offers 0.08% expenses and 1.51% yield. Educational content, not financial advice.

Compare IBB (iShares Biotechnology ETF) and XLV (Health Care Select Sector SPDR). This page examines fees, holdings and dividends, and how each fund tracks its market. IBB has a 0.44% expense ratio an...

Fund Snapshot

Key Fund Metrics

IBB

Metric

XLV

0.44%

Expense Ratio

0.08%

0.16%

Dividend Yield

1.51%

$10.45B

Net Assets

$43.50B

249

Holdings

64

Feb 5, 2001

Inception Date

Dec 16, 1998

–

Index Tracked

–

Health

Fund Category

Health

XLV costs about $36.00 less per year for every $10,000 invested.

Shared Top Holdings

Holding	IBB	XLV
GILDGilead Sciences, Inc.	8.37%	3.04%
AMGNAmgen Inc.	7.31%	3.46%

Discover More Comparisons

IBB vs XBI

Compare IBB and XBI ETFs. Analyze expense ratios, top holdings, dividend yields and tracking structures to understand their differences without financial advice

IBB vs IBBQ

Compare IBB and IBBQ ETFs on expense ratios, net assets, dividend yields, and top holdings. Index tracking details not available for either fund.

SPY vs XLV

Compare SPY and XLV across fees, holdings and dividends. Review tracking metrics for both SPDR ETFs to assess large-cap versus healthcare exposure.

Investment Analysis

IBB

Pros

IBB provides targeted exposure to biotechnology, distinct from broader health care indices.
With $10.4 billion net assets, the fund demonstrates substantial scale for its niche category.
It has a long operational history, having been established in February 2001.

Considerations

The expense ratio of 0.44% is significantly higher than typical broad market ETFs.
The dividend yield is minimal at 0.16%, offering little regular income to investors.
Holdings include volatile names like Moderna and Vertex, increasing portfolio risk.

XLV

Pros

The 0.08% expense ratio provides efficient access to the health care sector.
Net assets of $43.5 billion ensure high liquidity and robust trading volume.
A dividend yield of 1.51% offers more substantial regular income than IBB.

Considerations

It lacks the targeted biotech focus, offering broader diversified health care exposure.
Lilly accounts for 15.17% of the fund, creating significant single-stock concentration.
The index tracking methodology is not available for detailed verification.

Related Market Insights

Dow's Record Rally: Value Takes The Lead

The Dow Jones hits 48,000, signalling a major market shift. Discover how value stocks, especially healthcare & financials, are leading this rally. Invest with Nemo.

Aimee Silverwood | Financial Analyst

13 November 2025

Read Insight

Fed Policy Shift Explained: Defensive Investment Guide

Navigate Fed policy shifts with Nemo's defensive investing guide. Discover stable sectors like consumer staples & healthcare to protect your portfolio amid economic uncertainty.

Aimee Silverwood | Financial Analyst

5 October 2025

Read Insight

Related Market Insights

Dow's Record Rally: Value Takes The Lead

The Dow Jones hits 48,000, signalling a major market shift. Discover how value stocks, especially healthcare & financials, are leading this rally. Invest with Nemo.

Aimee Silverwood | Financial Analyst

13 November 2025

Read Insight

Fed Policy Shift Explained: Defensive Investment Guide

Navigate Fed policy shifts with Nemo's defensive investing guide. Discover stable sectors like consumer staples & healthcare to protect your portfolio amid economic uncertainty.

Aimee Silverwood | Financial Analyst

5 October 2025

Read Insight

About IBB and XLV

IBB (IBB)

The iShares Biotechnology ETF (IBB) offers investors diversified access to the dynamic biotechnology sector. As an exchange-traded fund, it tracks the performance of companies involved in medical research, drug development, and biotech innovation. With 249 holdings and net assets of USD 10.45 billion, IBB provides broad exposure to this capital-intensive industry. It carries an expense ratio of 0.44% and a modest dividend yield of 0.16%, reflecting the sector's focus on reinvestment for growth rather than income. Investors should note that biotechnology stocks can be highly volatile, driven by regulatory approvals and clinical trial outcomes. This ETF suits those seeking general exposure to healthcare innovation who understand that values can rise and fall significantly.

XLV (XLV)

Health Care Select Sector SPDR (XLV) is an exchange‑traded fund that provides diversified exposure to large-cap US health‑care companies across pharmaceuticals, biotechnology, medical devices, health‑care providers and insurers. It trades like a stock, offering a simple way to gain sector-specific exposure without selecting individual companies. Investors should note sector concentration risk — performance is tied to regulatory decisions, patent cycles, drug approvals and healthcare spending trends. XLV typically offers broad, liquid exposure and may distribute dividends, but yields and performance fluctuate. Fees for passive sector ETFs are generally low compared with active funds, though expenses reduce long‑term returns. Suitable for investors seeking targeted allocation to the health‑care sector within a diversified portfolio, XLV is not a substitute for personalised advice. This is general educational information only — values can fall as well as rise and past performance is not a reliable indicator of future results.

Which Baskets Do They Appear In?

Dow Record Rally: What's Next for Value Stocks?

The Dow Jones Industrial Average reached a historic high, closing above 48,000, fueled by the end of a government shutdown and a market rotation into value stocks. This shift suggests an investment opportunity in the outperforming healthcare and financial sectors, which are leading the charge.

Published: 13 November 2025

Explore Basket

Fed Policy Shift Explained: Defensive Investment Guide

A recent warning from a top Federal Reserve official about a weakening U.S. job market suggests a cautious approach to future monetary policy. This pivot could create investment opportunities in defensive, high-quality companies that can better withstand economic uncertainty.

Published: 5 October 2025

Explore Basket

Which Baskets Do They Appear In?

Dow Record Rally: What's Next for Value Stocks?

The Dow Jones Industrial Average reached a historic high, closing above 48,000, fueled by the end of a government shutdown and a market rotation into value stocks. This shift suggests an investment opportunity in the outperforming healthcare and financial sectors, which are leading the charge.

Published: 13 November 2025

Explore Basket

Fed Policy Shift Explained: Defensive Investment Guide

A recent warning from a top Federal Reserve official about a weakening U.S. job market suggests a cautious approach to future monetary policy. This pivot could create investment opportunities in defensive, high-quality companies that can better withstand economic uncertainty.

Published: 5 October 2025

Explore Basket

IBB vs XLV

Fund Snapshot